BACKGROUND: Ischemic stroke descent has a genetic basis. Stroke represents a complex trait, which is assumed to be polygenic. On this topic, the role of a wide number of candidate genes has been investigated in stroke through association studies.
Introduction
Stroke is believed to be a complex multifactorial and polygenic disease arising from a wide number of genegene and gene-environment interactions. Genetic factors could act by predisposing to conventional risk factors.
Studies on stroke genetics present some methodological difficulties. Therefore, the major line of multifactorial stroke investigation is the candidate-gene approach, which consists of identifying molecular variants within a functional relevant gene and establishing its function in stroke risk by association case-control. Following some reports of positive association ischemic disease, a wide number of candidate genes have been investigated in stroke, even if, so far, only a few polymorphisms have been consistently associated with stroke occurrence.
Most of these studies have been criticized for some bias related to small sample size, lack of classification by stroke phenotype or subtype, use of ethnically different populations, and unmatched controls (Flossmann et al., 2004 [1] ; Dichgans and Markus et al., 2005 [2] ). The differences in patient's characteristics together with the heterogeneity in study design, could explain much of the inconsistency between studies (Dichgans et al., 2007 [3] ).
Although association studies are considered as a powerful instrument to identify risk factors, both methodological and appropriate studies and replication of results are necessary to demonstrate a causal relationship between a genetic marker and stroke.
Therefore, the results of existing studies identified a list of possible candidate genes associated with stroke (Meschia et al., 2005 [4] ). In our work, we want to provide a meta analysis reporting studies published on genetic of stroke, and we analyzed only studies in which genotype frequency was reported. In our literature revision, we focused on ischemic stroke, excluding association analyses on hemorrhagic stroke patients.
The aim of this work is to give a panel of possible genes associated with ischemic stroke risk that could be useful both for future epidemiological data and for deciding new research strategies for stroke genetics studies.
Materials and Methods
Electronic databases (MEDLINE, EMBASE, PUBMED, SCOPUS…) were searched up until 2010 for all casecontrol studies evaluating any candidate gene and stroke.
The medical subject headings terms and text words used for the search were cerebrovascular disease, stroke, cerebral ischemia, and brain infarction in combination with polymorphism(s), mutation, genetic, genotype, or 
Data synthesis:
Thirty two candidate gene case-control studies in which the presence or absence of stroke were analyzed.
In total, 5 polymorphisms in 5 genes were identified. Table 1 ]. The prothrombin G20210A mutation was evaluated in 12 studies, with a total of 5644 cases and 13459 controls. The summary OR under a fixedeffects model showed that carriers of the mutation were 1.57 times more likely to develop stroke (95% CI, 1.23-2.89; P = .005) [ Table 2 ]. The Factor V Leiden G1691A mutation was evaluated in 12 studies, with a total of 7749 cases and 26101 controls. The summary OR under a fixed-effects model showed that carriers of the mutation were 1.43 times more likely to develop stroke (95% CI, 0.67-6.24; P=.005) [ Table 3 Table 4 ].
The apolipoprotein E genotype has been by far the most [5] 644 957 1,74(0,88-3,42) Szolnoki et al [6] 689 652 1.29 (1.00-1.65) Peterlin et al [7] 124 165 1,41(0.85-2.34) Markus et al 1995 [8] 101 188 1.98 (1.11-3.51) Kostulas et al 1999 [9] 100 93 0.99 (0.54-1.84) Pfohl et al 1998 [10] 91 297 0.94 (0.57-1.55) Zee et al 1999 [11] 338 338 1.10 (0.80-1.51) Casas et al [12] 2990 11305 1.21 (1.08-1.35) Zhang et al 2004 [13] 151 150 2.13 (1.10-4.13) Szolnoki et al [6] 407 295 1.3 (0.7-2.1) Ueda et al 1995 [14] 488 73 1.26 (0.84-1.88) Cato et al 1996 [15] 406 137 0.94 (0.65-1.35) Kario et al 1996 [16] 138 P=.002) [ Table 5 ].
Comments
In this comprehensive meta-analysis, 3 (47%) of the 5 candidate polymorphisms analyzed significantly increased the risk of stroke. In 24 of these studies (ACE I/D, factor V Leiden, MTHFR C677T, prothrombin G20210A, and apolipoprotein E), the number of cases included per gene was more than 1000, allowing more precise estimates to be made of the effect of these genes than from any single study. Most candidate genes assessed in stroke thus far have been evaluated initially for their potential role in ischemic disease. Therefore, up to now, most genetic studies have focused on genes involved in thrombosis and coagulation (factor V Leiden, prothrombin, and MTHFR, also genes regulating other well-established risk factors for stroke (e.g., hypertension, diabetes mellitus, and hyperlipidemia (ACE and apolipoprotein E) are studied. [17] 125 149 2.03 (0.47-8.66) Szolnoki et al [6] 689 652 1.18 (0.32-4.43) Smiles et al [18] 182 453 1.25 (0.46-3.39) Gomez Garcia et al [19] 49 87 2.36 (0.60-9.23) Hankey et al [20] 219 205 1.91 (0.56-6.43) Lopaciuk et al [21] 100 238 0.95 (0.18-4.99) Egan et al [22] 38 635 0.60 (0.03-10.26) Voetsch et al [23] 114 119 2.15 (0.52-8.80) Margaglione et al 1999 [24] 202 1036 1.20 (0.59-2.43) Ridker et al 1999 [25] 259 1774 1.10 (0.57-2.10) Iniesta et al 1999 [26] 124 202 0.40 (0.04-3.64) Casas et al [12] 3028 7131 1.44 (1.11-1.86) Nowak-Gottl et al 1999 [27] 148 296 4. [17] 125 149 1.45 (0.43-4.88) Szolnoki et al [6] 689 652 1.54 (1.03-2.30) Madonna et al [29] 132 262 0.81 (0.33-2.00) Juul et al [30] 231 7907 0.92 (0.56-1.52) Zunker et al [31] 471 112 0.95 (0.38-2.38) Lopaciuk et al [21] 100 238 0.71 (0.19-2.62) Hankey et al [20] 219 205 2.40 (0.74-7.79) Voetsch et al [23] 114 119 0.73 (0.23-2.38) Casas et al [12] 4588 13798 1.33 (1.12-1.58) Iniesta et al 1999 [26] 124 202 0.98 (0.23-4.16) Margaglione et al 1999 [24] 202 1036 4.03 (2.46-6.60) Grossmann et al 2002 [32] 93 186 3.19 (1.38-7.39) Lalouschek et al [33] 468 468 
4: Results of published studies of the association between the methylenetetrahydrofolate reductase C677T polymorphism and ischemic stroke. Odds ratios for the outcome compared individuals homozygous for the T allele (T/T) with those heterozygous individuals (C/T) plus wild type (C/C). CI indicates confidence interval.
MTHFR Publication CasesControls OR Roshan Ariyaratnam et al 2007 [5] 1859 2380 1.18 (0.90-1.56) Roshan Ariyaratnam et al 2007 [5] 478 541 1.34 (0.87-2.06) Pezzini et al [17] 125 149 1.51 (0.82-2.79) Szolnoki et al [6] 689 652 1.38 (0.94-2.00) Pezzini et al [35] 31 36 1.19 (0.27-5.19) Madonna et al [29] 132 262 1.42 (0.84-2.38) McIlroy et al [36] 63 71 0.56 (0.05-6.29) Lopaciuk et al [21] 100 238 1.11 (0.54-2.30) Topic et al [37] 56 124 17.57 (2.11-146.58) Voetsch et al [23] 114 119 1.31 (0.62-2.81) Eikelboom et al [38] 215 205 1.04 (0.57-1.90) Gross et al [39] 84 112 1.29 (0.59-2.85) Casas et al [12] 3387 4597 1.24 (1.08-1.42) Casas et al. [12] 6324 7604 1.26 (1.14-1.40) Total 13657 17090 1,23(0,61-1,47) [36] 64 71 0.93 (0.38-2.24) Topic et al [37] 56 124 2.45 (0.91-6.55) MacLeod et al 2001 [40] 266 225 0.70 (0.47-1.04) Frikke-Schmidt et al 2001 [41] 286 8938 1.12 (0.87-1.44) Catto et al 2000 [24] 515 289 0.88 (0.64-1.21) Margaglione et al 1998 [15] 108 1000 0.32 (0.16-0.66) Kessler et al 1997 [42] 220 223 1.18 (0.76-1.84) Sudlow et al 2006 [43] 5961 17965 1.11 (1.01-1.22) Banerjee et al 2007 [44] 988 1441 1.47 (1-2.15) Pezzini et al 2004 [45] 124 147 2.29 (1.10-4.76) Baum et al 2006 [46] 246 336 1. The factor V Leiden mutation causes activated protein After activation, the mutated factor V is less efficiently degraded by activated protein C than normal factor V, resulting in increased thrombin generation and a hypercoagulable state, with a 5-10-fold increased risk of thrombosis in heterozygotes and a 50-100-fold increased risk in homozygotes which may explain the increased risk of stroke in carriers of this mutation observed in this study (OR=1.43 (0.67-6.24)). In our study, the risk factor is varying from 0.19 found by Lopaciuk et al [21] to 38 found in the series of Lalouschek et al. [33] 02-1.25) ).
In the 12 works studied in our meta-analysis, the OR is sensibly varying between 0.5 and 2.
Long-term differences of 5 µmol/L in the serum concentration of homocysteine are associated with a 59% increase in the risk of stroke. The C677T mutation in the MTHFR gene, which encodes an amino acid substitution (A222V), renders the enzyme thermolabile and reduces metabolism of homocysteine (OR=1.23 (0.61-1.47)). The MTHFR remains the most controversial genetics factor with an average of OR from 0.05 in
McIlroy et al, [36] to 146.58 in the work of Topic et al. [37] Carriers of the apolipoprotein E ε4 allele, which affects serum cholesterol, and which has been associated with a moderate increase in the risk of coronary heart disease, are at a substantially higher risk of stroke (OR=0.95 (0.77-1.14)).
The results of our meta-analysis about the five stroke genes are summarized in Figure 1 . 
